Portage Biotech and Compedica Forge $5M Alliance to Revolutionize Diabetic Foot Ulcer Care With Breakthrough Device
Portage Biotech’s $5M equity swap with Compedica aims to disrupt the $4B diabetic foot ulcer market—major clinical trial results set for Q4 2025.